A recent report on the results of a series of unannounced “vape shop” visits by federal inspectors raises questions about quality-assurance in the preparation of some e-cigarette products.
Vape shops typically sell products, including electronic nicotine delivery devices and “e-liquids” solutions that are atomized by heating elements within the devices. When inhaled, the resulting vapor delivers nicotine, flavorings and other additives to the user. Continue reading
If you are familiar with Drugs@FDA, you know that the website allows you to quickly look up a drug by its name (brand), the active ingredient (generic), or application number. But if you frequently work on the go or need to look up something quickly while away from your computer, you now can download the FDA’s new app, Drugs@FDA Express (iOS/Apple and Android/Google), to see much of the same information.
Released in late March, the app is pretty basic, but often that’s the best kind of app. It loads quickly, isn’t overly cluttered and has simpler user-friendly interface. The opening page is straightforward. Continue reading
Photo: Pia Christensen/AHCJCharles Piller, Paul Raeburn and Christopher Robertson (left to right) discussed the science of genetic testing on the first day of Health Journalism 2018.
Health insurers struggle to understand whether genetic tests give physicians actionable information about how to diagnose and treat patients’ illness. If health insurers struggle, then journalists certainly will as well. For example, see this tip sheet that Beth Daley (@BethBDaley) wrote for AHCJ when she was at the New England Center for Investigative Reporting.
Genetic testing holds immense promise, but as speakers explained during the “Science of Genetic Testing” session at Health Journalism 2018, misuse and misinterpretation of these tests have undercut that promise. Continue reading
After decades of unfulfilled promises and setbacks, the field of gene therapy broke through with three FDA-approved products last year, ushering in what is likely to be a rapid escalation of new treatments for some of the rarest and most debilitating diseases.
“Part of the idea of the Human Genome project was that once we had the identity of all the genes, it would be important and straight forward for us to development more therapeutic options for people with serious inherited diseases, said Katherine High, M.D., president and director of research and development for Philadelphia-based Spark Therapeutics. “But it turned out this took a little longer to do than the Human Genome project.” Continue reading
Photo: CDC/Courtesy of Larry Stauffer, Oregon State Public Health LaboratoryA positive result of a phage test showing diminished growth (arrowhead) where a gamma phage suspension had been applied.
A desire to put a human face to antibiotic resistance led reporter Chris Dall to dig into the relatively unknown world of viral research aimed at killing superbugs.
Dall began investigating bacteriophages, which are viruses that kill bacteria, when he was assigned a story to write about a study that appeared in the scientific journal, Antimicrobial Agents and Chemotherapy in August 2017. The report dryly described a method of using viruses to save a 68-year-old man, who was dying from an antibiotic-resistant infection. Continue reading
The FDA’s new guidance on digital health paves way for more tools that aim to support physicians and patients.
Expect to see a slew of new software programs and tools aimed to support clinicians and patients to make informed treatment decisions, after the Food and Drug Administration released its long-awaited draft rule last week on clinical decision support (CDS) systems. Continue reading